Ajanta Pharma share price
NSE: AJANTPHARMBSE: 532331Pharmaceuticals & BiotechnologyMid Cap
Ajanta Pharma Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 2000 on NSE, Jun 2000 on BSE
Last close ₹3,459.80up ₹106.20 (3.17%)BSE ₹3,451.70
Share price at the NSE close on 28 Oct 2026. Previous close ₹3,353.60.
28 Oct: open ₹3,354.00, high ₹3,516.40, low ₹3,342.90
52-week range of traded prices to 28 Oct 2026
₹2,382.00Low, 28 Oct 2025₹3,796.00High, 18 Aug 2026
- Next results date: the board meets on 30 Oct 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹43,233 Cr236th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 38.10
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 9.55
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 1.73%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 27.3%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 27.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.05
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 43,73334.1% delivered
About Ajanta Pharma
Ajanta Pharma Limited is a Mumbai-based specialty pharmaceutical company that makes formulations (finished medicines).12 It sells branded generics (generic medicines sold under its own brand names) in India, Asia and Africa, generic medicines in the United States, and antimalarial medicines in Africa through multilateral aid agencies.13 Its brands focus on chronic therapies: heart, diabetes, eye, skin, pain and gynaecology.4
The company reports a single operating segment, pharmaceutical and related products.5 Its customers include distributors, stockists, healthcare professionals, hospitals, government institutions and pharmacists.6 Abroad it works through wholly owned subsidiaries in the United States, the Philippines, Mauritius, Nigeria and Ireland, the Irish one set up in the year to Mar 2026.78
It was incorporated in 1979.9 Its promoters include chairman Mannalal B. Agrawal, his brother and vice chairman Madhusudan B. Agrawal, and Mannalal's sons Yogesh M. Agrawal and Rajesh M. Agrawal, the managing director and joint managing director.109
Ajanta Pharma key points
Results
- In the quarter to Jun 2026, consolidated revenue from operations was ₹1,626 crore, against ₹1,303 crore a year earlier, and net profit was ₹334 crore, against ₹255 crore.111213
- In the quarter to Jun 2026, EBITDA (earnings before interest, tax, depreciation and amortisation) was ₹424 crore, 26% of revenue from operations, up 21% from ₹351 crore a year earlier.14
- In the year to Mar 2026, consolidated revenue from operations rose 17% to ₹5,453 crore and profit after tax rose 15% to ₹1,056 crore.15
- In the year to Mar 2026, EBITDA was ₹1,395 crore, up 11%. Adjusted EBITDA rose 18% to ₹1,498 crore, a 27% margin; it leaves out a ₹103 crore loss on currency hedges, which the company says a ₹97 crore currency gain in other income offset.1617
Market position
- The company ranked 24th among pharmaceutical companies in India in the year to Mar 2026, up from 26th a year earlier.18
- In the year to Mar 2026 it ranked 2nd in ophthalmology (eye care) in India, 13th in dermatology (skin care), up from 16th, and 17th in cardiology.19
- In the year to Jun 2026, its sales in India as measured by market-research data grew 15.1%, against 11.1% for the Indian pharmaceutical market as a whole.20
Revenue mix
- Sales by business212223
Item quarter to Jun 2026 quarter to Jun 2025 Branded generics, India ₹509 crore ₹409 crore Generics, United States ₹487 crore ₹310 crore Branded generics, Africa ₹295 crore ₹228 crore Branded generics, Asia ₹255 crore ₹304 crore Antimalarials for aid agencies, Africa ₹70 crore ₹38 crore - Main therapies' share of India sales, year to Jun 2026, from market-research data rather than the company's own accounts24
Item year to Jun 2026 Cardiology 37% Ophthalmology 29% Dermatology 22% Pain management 10%
Where revenue comes from
- The company is present in more than 34 countries: India, the United States, 21 countries in Africa and 11 in the rest of Asia.25
- Exports made up 69% of turnover in the year to Mar 2026.26
- More than 6,050 medical representatives (sales staff who visit doctors) promote its products, more than 3,750 of them in India.2728
US generics
- US generics sales were ₹1,557 crore in the year to Mar 2026, up 49%, and made up 29% of total revenue.29
- At the end of Jun 2026 it held 55 active ANDAs (abbreviated new drug applications, the US approval to sell a generic), excluding 5 tentative ones, with 17 awaiting approval and 51 products on sale.30
- In US generics, it received 3 ANDA approvals and launched 2 products in the quarter to Jun 2026.31
- The company stated in its annual report for the year to Mar 2026 that it targets 8 to 12 ANDA filings in the year to Mar 2027, after filing 5 in the year to Mar 2026.32
Plants and capacity
- It makes its medicines at 7 plants in India, the main ones at Paithan (Maharashtra), Dahej (Gujarat), Guwahati (Assam) and Pithampur (Madhya Pradesh).3334
- 2 of the plants are approved by the US FDA (the US drug regulator) and the others comply with the WHO's good manufacturing practice standards.34
- Capital spending was ₹330 crore in the year to Mar 2026, including maintenance, an oral solids block and a liquids plant at Pithampur and a new office in Andheri, Mumbai.35
Research and development
- More than 850 scientists work in research and development (R&D), on complex products using advanced drug delivery systems.36
- R&D spending was ₹252 crore in the year to Mar 2026, 5% of revenue, against ₹224 crore a year earlier.36
- The company stated in its annual report for the year to Mar 2026 that it expects R&D spending to stay at similar levels.36
Last updated
All 39 sources, each with its page
- 1. Annual report, 18 Jun 2026, page 14
- 2. Annual report, 18 Jun 2026, page 13
- 3. Annual report, 18 Jun 2026, page 16
- 4. Investor presentation, 30 Jul 2026, page 7
- 5. Annual report, 18 Jun 2026, page 96
- 6. Annual report, 18 Jun 2026, page 41
- 7. Annual report, 18 Jun 2026, page 42
- 8. Annual report, 18 Jun 2026, page 19
- 9. Annual report, 18 Jun 2026, page 13
- 10. Annual report, 18 Jun 2026, page 29
- 11. Investor presentation, 30 Jul 2026, page 32
- 12. Investor presentation, 30 Jul 2026, page 32
- 13. Investor presentation, 30 Jul 2026, page 33
- 14. Investor presentation, 30 Jul 2026, page 32
- 15. Annual report, 18 Jun 2026, page 19
- 16. Annual report, 18 Jun 2026, page 16
- 17. Annual report, 18 Jun 2026, page 5
- 18. Annual report, 18 Jun 2026, page 8
- 19. Annual report, 18 Jun 2026, page 15
- 20. Investor presentation, 30 Jul 2026, page 13
- 21. Investor presentation, 30 Jul 2026, page 30
- 22. Investor presentation, 30 Jul 2026, page 31
- 23. Investor presentation, 30 Jul 2026, page 20
- 24. Investor presentation, 30 Jul 2026, page 15
- 25. Investor presentation, 30 Jul 2026, page 5
- 26. Annual report, 18 Jun 2026, page 41
- 27. Investor presentation, 30 Jul 2026, page 6
- 28. Investor presentation, 30 Jul 2026, page 12
- 29. Annual report, 18 Jun 2026, page 10
- 30. Investor presentation, 30 Jul 2026, page 8
- 31. Investor presentation, 30 Jul 2026, page 22
- 32. Annual report, 18 Jun 2026, page 10
- 33. Investor presentation, 30 Jul 2026, page 28
- 34. Annual report, 18 Jun 2026, page 11
- 35. Annual report, 18 Jun 2026, page 17
- 36. Annual report, 18 Jun 2026, page 11
- 37. Annual report, 18 Jun 2026, page 19
- 38. Annual report, 18 Jun 2026, page 34
- 39. Annual report, 18 Jun 2026, page 35
Results
Consolidated; ₹ crore.Ajanta Pharma quarterly results
- Revenue growth, 12 monthsRevenue growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +20.2%
- Net profit growth, 12 monthsNet profit growth, 12 months. The last twelve months against the twelve before them. Left empty where the earlier figure was nought or a loss: growth out of a loss has no percentage.
- +22.0%
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹1,626 Crup 14.37%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹334 Crup 25.32%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 20.6%
Revenue by quarter
Peak revenue ₹1,626 Cr, quarter to Jun 2026; lowest ₹1,146 Cr, quarter to Dec 2024
Net profit by quarter, a loss in red
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1,187 | 1,146 | 1,170 | 1,303 | 1,354 | 1,375 | 1,422 | 1,626 |
| Net profit | 216 | 233 | 225 | 255 | 260 | 274 | 267 | 334 |
| Net margin | 18.2% | 20.3% | 19.2% | 19.6% | 19.2% | 19.9% | 18.8% | 20.6% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026, against the year before
- RevenueRevenue. The pill is the change in revenue against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹5,453 Crup 17.31%
- Net profitNet profit. The pill is the change in net profit against the year before: this period's figure divided by that one's, less one, in per cent.
- ₹1,056 Crup 14.73%
- Net margin
- 19.4%
Revenue by year
Peak revenue ₹5,453 Cr, year to Mar 2026; lowest ₹2,002 Cr, year to Mar 2017
Net profit by year, a loss in red
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,002 | 2,131 | 2,055 | 2,588 | 2,890 | 3,341 | 3,743 | 4,209 | 4,648 | 5,453 |
| Net profit | 507 | 469 | 387 | 468 | 654 | 713 | 588 | 816 | 920 | 1,056 |
| Net margin | 25.3% | 22.0% | 18.8% | 18.1% | 22.6% | 21.3% | 15.7% | 19.4% | 19.8% | 19.4% |
Consolidated. Years to March. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the year to Mar 2026 the company reports one business segment, Pharmaceutical, which carries all its revenue.
Valuation
Today, against the company's own history.Ajanta Pharma PE ratio and valuation
Price to earnings
At or below today's level on 90% of 2,478 trading days over the last 10 years.
LowestHighest
Its median27.28Industry median27.98
Price to book
At or below today's level on 92% of 1,980 trading days since Nov 2018.
LowestHighest
Its median5.50Industry median2.94
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 89% of 2,471 trading days over the last 10 years.
LowestHighest
Its median0.83%Industry median0.48%
Where the return came from
Yearly rates to Mar 2026, per-share figures restated for splits and bonuses.
| Over | Return a year | Earnings growth | Change in P/E | Dividend yield |
|---|---|---|---|---|
| 1 year | +7.9% | +14.9% | −6.9% | 1.0% |
| 3 years | +33.8% | +22.6% | +8.0% | 1.5% |
| 5 years | +19.7% | +11.0% | +6.8% | 1.1% |
Return is price growth plus the average dividend yield. Change in P/E is (1 + price growth) / (1 + earnings growth) - 1, so the parts compound rather than add.
Mutual fund holdings
197 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 80 of the 111 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future. 1 more fund filed its first portfolio on record, holding it.All 197 funds holding Ajanta Pharma
- Bought for the first timeBought for the first time. Funds that held it at the month's end and had not held it in any month on record before.
- 4
- Bought againBought again. Funds that held it at the month's end, had not held it the month before, and held it in an earlier month.
- 1
- AddedAdded. Funds that held more shares than at the end of the month before.
- 85
- CutCut. Funds that held fewer shares than at the end of the month before.
- 26
- Held unchangedHeld unchanged. Funds that held the same number of shares as at the end of the month before.
- 80
- Sold outSold out. Funds that held it at the end of the month before and hold none at this month's end. Sold out in the glossary
- 5
| Fund | |||
|---|---|---|---|
 Nippon India Small Cap FundNippon India Mutual Fund | 16,74,471 | 0.75% | ₹606.3 Cr |
 Kotak Flexi Cap FundKotak Mahindra Mutual Fund | 16,17,147 | 1.10% | ₹585.5 Cr |
 UTI Flexi Cap FundUTI Mutual Fund | 13,17,224 | 2.12% | ₹476.9 Cr |
| Kotak-Small Cap FundKotak Mahindra Mutual Fund | 10,86,134 | 2.05% | ₹393.3 Cr |
| Kotak Large & Mid Cap FundKotak Mahindra Mutual Fund | 9,85,144 | 1.17% | ₹356.7 Cr |
| Nippon India Pharma FundNippon India Mutual Fund | 9,13,918 | 3.61% | ₹330.9 Cr |
 HDFC Large & Mid Cap FundHDFC Mutual Fund | 8,97,224 | 1.14% | ₹324.9 Cr |
 Canara Robeco Small Cap FundCanara Robeco Mutual Fund | 7,47,040 | 1.94% | ₹270.5 Cr |
| Nippon India Multi Cap FundNippon India Mutual Fund | 7,42,553 | 0.50% | ₹268.9 Cr |
| UTI Mid Cap FundUTI Mutual Fund | 7,07,737 | 2.15% | ₹256.3 Cr |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Promoter and insider buying and selling
Trades made since 29 Oct 2025.Ajanta Pharma insider trading
Bought on the marketBought on the market. The value each filer stated for its purchases on the exchange, added up; gifts, transfers and pledges are not counted. A purchase filed with no value is counted under the sum, not in it. Sold on the marketSold on the market. The value each filer stated for its sales on the exchange, added up; gifts, transfers and pledges are not counted. A sale filed with no value is counted under the sum, not in it.
- Promoters and promoter group0 purchases, 1 saleNo purchase₹1,024 CrNetNet. The value bought on the market less the value sold, over the trades whose filers stated a value.−₹1,024 Cr2 pledges created · 55 pledge filings of unclear kind
- Others0 purchases, 6 salesNo purchase₹2.72 CrNet−₹2.72 Cr
Bought and sold count trades on the market only. A pledge is shares given to a lender as security for a loan; a lender invokes it by selling them.
Ajanta Pharma competitors and peers
Pharmaceuticals, 215 listed companies, priced on 28 Oct 2026. The table lists the 8 companies closest to Ajanta Pharma in market cap.Healthcare companies
Where the company sits among the companies nearest its size
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 BioconBIOCON | 57,153 | 115.39 | 1.68 | +9.8% | +28.6% | 1.8% | 2.9% | 0.14% |
 Abbott IndiaABBOTINDIA | 55,833 | 34.58 | 11.69 | +6.3% | +11.2% | 35.9% | 39.6% | 2.50% |
 Gland PharmaGLAND | 50,312 | 44.57 | 4.86 | +17.6% | +46.5% | 11.6% | 12.4% | 0.66% |
 IPCA LaboratoriesIPCALAB | 48,978 | 37.39 | 6.07 | +10.6% | +68.2% | 17.4% | 17.6% | 0.31% |
 GlaxoSmithKline PharmaceuticalsGLAXO | 42,318 | 39.62 | 18.66 | +5.8% | +12.4% | 50.6% | 56.3% | 2.28% |
 Emcure PharmaceuticalsEMCURE | 35,571 | 35.17 | 7.19 | +18.4% | +35.9% | 21.5% | 25.2% | 0.19% |
 Sai Life SciencesSAILIFE | 31,591 | 87.33 | 12.72 | – | – | 15.7% | 18.7% | 0.00% |
 WockhardtWOCKPHARMA | 31,091 | 76.02 | 6.29 | +18.4% | – | 8.8% | 7.4% | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Ajanta Pharma dividend history
Dividend per share, ₹, restated for later splits and bonuses
Dividend per share. The dividends declared for the year, each restated to today's share count by the splits and bonuses after its own ex-date, added up. Dividend per share in the glossaryHighest ₹51.00 a share, year to Mar 2024.
| Ex-date | Type | Per share |
|---|---|---|
| 5 Aug 2026 | Interim | ₹32.00 |
| 10 Nov 2025 | Interim | ₹28.00 |
| 6 Nov 2024 | Interim | ₹28.00 |
| 8 Feb 2024 | Interim | ₹26.00 |
| 4 Aug 2023 | Interim | ₹10.00 |
| 4 Aug 2023 | Special | ₹15.00 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Ajanta Pharma announcements
Oct 2026
15 Oct · Analysts
15 Oct · Board meeting
Sep 2026
30 Sep · General Updates
Ajanta Pharma share price by year
Each calendar year to 2025.Ajanta Pharma share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 2,768.90 | −5.6% | 2,998.25 | 2,374.45 |
| 2024 | 2,932.20 | +40.7% | 3,426.50 | 2,064.95 |
| 2023 | 2,083.65 | +71.9% | 2,083.65 | 1,159.95 |
| 2022 | 1,211.95 | −18.7% | 1,543.20 | 1,105.40 |
| 2021 | 1,490.37 | +36.9% | 1,596.47 | 1,099.87 |
| 2020 | 1,088.80 | +67.6% | 1,148.50 | 650.43 |
| 2019 | 649.70 | −17.8% | 787.80 | 587.07 |
| 2018 | 790.47 | −20.5% | 1,059.10 | 607.73 |
| 2017 | 994.30 | −16.3% | 1,229.80 | 753.93 |
| 2016 | 1,188.53 | +33.9% | 1,395.37 | 773.17 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before.
Recent sessions
The 9 trading days to 27 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 27 Oct 2026 | 3,385.00 | 3,529.30 | 3,330.00 | 3,353.60 | 3,388.21 | 1,74,374 | 50.1% |
| 26 Oct 2026 | 3,285.00 | 3,459.00 | 3,260.00 | 3,381.00 | 3,366.57 | 1,07,072 | 30.6% |
| 23 Oct 2026 | 3,261.40 | 3,349.60 | 3,224.30 | 3,283.90 | 3,289.34 | 1,54,847 | 62.5% |
| 22 Oct 2026 | 3,215.10 | 3,291.20 | 3,199.90 | 3,270.60 | 3,251.76 | 58,123 | 51.5% |
| 21 Oct 2026 | 3,285.00 | 3,314.30 | 3,250.00 | 3,260.20 | 3,263.32 | 53,439 | 70.4% |
| 19 Oct 2026 | 3,325.90 | 3,387.50 | 3,285.00 | 3,298.90 | 3,325.67 | 36,644 | 50.4% |
| 16 Oct 2026 | 3,372.50 | 3,381.00 | 3,308.30 | 3,329.00 | 3,345.03 | 38,358 | 54.4% |
| 15 Oct 2026 | 3,330.00 | 3,387.70 | 3,313.70 | 3,359.40 | 3,355.09 | 1,03,485 | 54.7% |
| 14 Oct 2026 | 3,328.20 | 3,377.20 | 3,269.90 | 3,299.00 | 3,314.62 | 74,868 | 54.4% |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Bonus shares and stock split history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 22 Jun 2022 | Bonus | 0.6667 | Holders received 1 bonus share for every 2 held. |
| 20 Mar 2015 | Split | 0.4000 | Every 2 shares became 5. |
| 17 Sep 2013 | Bonus | 0.6667 | Holders received 1 bonus share for every 2 held. |
| 9 Aug 2012 | Split | 0.5000 | Each share became 2. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout.
Company details
- NSE symbol
- AJANTPHARM
- BSE code
- 532331
- ISIN
- INE031B01049
- Industry
- Pharmaceuticals & Biotechnology
- Website
- www.ajantapharma.com
- CIN
- L24230MH1979PLC022059
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 1979
- Registered office
- Ajanta Tower, 54-A, M.V. Road, Chakala, Andheri (East), Mumbai 400093, Maharashtra
- Share registrar
- MUFG Intime India Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments
In Nifty 500, BSE 500, Nifty Midcap 150, BSE 150 MidCap Index, BSE MidCap, Nifty Total Market